Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Voltage-gated calcium channel (VGCC) antibodies are a specific type of antibody that target the voltage-gated calcium channels in the body. These antibodies are primarily associated with Lambert-Eaton syndrome, a rare autoimmune disorder that affects the presynaptic nerve terminals, leading to significant muscle weakness, particularly in the extremities, as well as reduced tendon reflexes and various autonomic dysfunctions. In addition to Lambert-Eaton syndrome, VGCC antibodies are also linked to cerebellar degeneration, which can result in coordination and balance issues due to the impairment of the cerebellum's function. Notably, more than half of the patients who test positive for VGCC antibodies may also have an underlying neoplastic tumor, most commonly small cell lung cancer. VGCCs play a crucial role in the physiological process of depolarizing the cell membrane, which allows calcium ions to enter the cell in response to an action potential, thereby facilitating electrical signaling and initiating various cellular mechanisms. These calcium channels are present in various tissues, including smooth and skeletal muscle fibers, endocrine cells, and nerve cells. The detection of VGCC antibodies is typically performed using a radioimmunoassay, which can identify these antibodies in up to 90% of patients with Eaton-Lambert syndrome, as well as in all patients who have both Eaton-Lambert syndrome and small cell lung cancer. In this assay, radiolabeled antigens specific to the VGCC antibody are introduced into a serum sample from the patient, allowing for the identification of antibodies as they form immune complexes by binding to these traceable antigens.
© Copyright 2026 Coding Ahead. All rights reserved.
The testing for voltage-gated calcium channel (VGCC) antibodies is indicated in the following scenarios:
The procedure for detecting voltage-gated calcium channel antibodies involves several key steps:
After the procedure, the serum sample is processed, and results are typically available within a specified timeframe, depending on the laboratory's protocols. Patients may not require any specific post-procedure care, as the test is non-invasive and does not involve any significant risks. However, it is essential for healthcare providers to discuss the results with the patient, especially if VGCC antibodies are detected, as this may indicate the presence of Lambert-Eaton syndrome or an associated neoplastic tumor, necessitating further evaluation and management.
| Short Descr | VOLTAGE-GTD CA CHNL ANTB EA | Medium Descr | VOLTAGE-GATED CALCIUM CHANNEL ANTIBODY EACH | Long Descr | Voltage-gated calcium channel antibody, each | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 3 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | AY | Item or service furnished to an esrd patient that is not for the treatment of esrd | GW | Service not related to the hospice patient's terminal condition | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Added | Code added |
Get instant expert-level medical coding assistance.